Business Wire

Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT

2.7.2020 12:00:00 EEST | Business Wire | Press release

Share

Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode.

With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology.

Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the implementation of this technology. Rechargeable and non-rechargeable lithium batteries – which power everyday devices such as smartphones, tablets, cameras, laptops and power banks – are classified as dangerous goods by the air-transportation industry because of their ability to ignite during flights. Since 2006,1 the US Federal Aviation Administration has recorded more than 260 incidents of smoke, heat, fire or explosion involving lithium batteries in air cargo or baggage. Furthermore, the transporting of flammable liquids and solids as well as compressed and liquefied gasses continues to pose threats to airport operators, airlines and cargo companies.

To be shipped by air, dangerous goods require special treatment and additional declarations according to International Air Transport Association (IATA) regulations. Through automatic object recognition, iCMORE supports image operators by detecting dangerous goods without increasing their workload, as it requires little training and generates very low false-alarm rates.

“As a trusted partner to airports across the world, we are striving to develop new technologies to counteract new and emerging threats,” said Richard Thompson, Global Director Aviation for Smiths Detection. “The iCMORE modules for both lithium batteries and dangerous goods further enhance the HI-SCAN 10080 XCT, streamlining the hold-baggage and air-cargo screening process without burdening operators. Using this technology will not only make aviation safer but can also help prevent costly fines for shipping dangerous goods in a non-compliant way as well as helping safeguard the global supply of goods, which is essential given the need for medical supplies – for example – to be shipped without interruption.”

This launch follows the release of the iCMORE lithium-batteries module for the HI-SCAN 100100V-2is and HI-SCAN 100100T-2is in August 2019 and the HI-SCAN 6040 CTiX for weapons in cabin baggage.

ENDS

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information visit http://www.smithsdetection.com.


1 https://www.faa.gov/hazmat/resources/lithium_batteries/media/Battery_incident_chart.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Bettina Meurer, Smiths Detection, Global Aviation Marketing Manager –
E: Bettina.Meurer@smithsdetection.com
T: +49 611 9412 189
M: +49 162 2779 760

Sophie Mills, Smiths Detection, Global Communications Manager –
E: Sophie.Mills@smithsdetection.com
T: + 44 (0)73 8423 6474

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye